Leukopenia due to parvovirus B19 in a Crohn's disease patient using azathioprine

Digestion

Volumn 79, Issue 4, 2009, Pages 211-214

  Van Asseldonk, Dirk P ^a,b   Kanis, Bernardina M ^a   De Boer, Nanne K H ^a   Van Bodegraven, Ad A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Azathioprine; Crohn's disease; Leukopenia; Parvovirus B19

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; THIOPURINE METHYLTRANSFERASE;

ABSENCE OF SIDE EFFECTS; ADULT; ANOREXIA; ARTICLE; BONE MARROW CELL; CASE REPORT; CELL PROLIFERATION; CHRONIC DISEASE; CROHN DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERYTHEMA INFECTIOSUM; FEMALE; FEVER; HUMAN; IMMUNE DEFICIENCY; LABORATORY TEST; LEUKOPENIA; LONG TERM CARE; MALAISE; ONSET AGE; PARVOVIRUS; PRIORITY JOURNAL; RASH; SHIVERING; TREATMENT DURATION;

ADULT; AZATHIOPRINE; CROHN DISEASE; ERYTHEMA INFECTIOSUM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; PARVOVIRUS B19, HUMAN;

EID: 65449156896     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000212778     Document Type: Article

References (22)

1. Pearson DC, May GR, Fick G, Sutherland LR: Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;2:CD000067.
2. Timmer A, McDonald JW, MacDonald JK: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1): CD000478.
3. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soule JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F: Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-1030.
4. Gisbert JP, Gomollon F: Thiopurine-induced mye lotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103:1783-1800.
5. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-713.
6. Sahasranaman S, Howard D, Roy S: Clinical pharmacology and pharmacogenetics of t hiopurines. Eur J Clin Pharmacol 2008;6 4:753-767.
7. Gilissen LP, Derijks LJ, Verhoeven HM, Bierau J, Hooymans PM, Hommes DW, Engels LG: Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig Liver Dis 2007;39:182-186.
8. Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, Pousette A, Almer S: Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006;55:1423-1431.
9. Roberts RL, Gearry RB, Bland MV, Sies CW, George PM, Burt M, Marinaki AM, Arenas M, Barclay ML, Kennedy MA: Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenet Genomics 2008;18:434-438.
10. Korelitz BI, Zlatanic J, Smith MJ, Lipe RJ, Baiocco PJ, Gleim GW: Significance of WBC differential when leukopenia is induced by 6-MP for IBD. Gastroenterology 1997;113:1810-1811.
11. Green M, Michaels MG: Infectious complications of immunosuppressive medications in organ transplant recipients. Pediatr Infect Dis J 2007;26:443-444.
12. de Boer NK, van Bodegraven AA, de Graaf P, van der Hulst RW, Zoetekouw L, van Kuilenburg AB: Paradoxical Elevated Thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. Ther Drug Monit 2008;30: 390-393.
13. Cossart YE, Field AM, Cant B, Widdows D: Parvovirus-like particles in human sera. Lancet 1975;1: 72-73.
14. Jordan JA: Human Parvoviruses;in Murray PR, Baron EJ, Jorgenson JH, Landry M, Pfaller MA (eds): Manual of Clinical Microbiology. Washington, ASM Press, 2007, vol 9, pp 1622-1630.
15. Brown KE, Young NS: Parvovirus B19 infection and hematopoiesis. Blood Rev 1995;9:176-182.
16. Muir K, Todd WT, Watson WH, Fitzsimons E: Viral-associated haemophagocytosis with parvovirus-B19-related pancytopenia. Lancet 1992;339:1139-1140.
17. Heegaard ED, Schmiegelow K: Serologic study on parvovirus b19 infection in childhood acute lymphoblastic leukemia during chemotherapy: clinical and hematologic implications. J Pediatr Hematol Oncol 2002;24:368-373.
18. Kurtzman GJ, Cohen B, Meyers P, Amunullah A, Young NS: Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia. Lancet 1988;ii:1159-1162.
19. Istomin V, Sade E, Grossman Z, Rudich H, Sofer O, Hassin D: Agranulocytosis associated with parvovirus B19 infection in otherwise healthy patients. Eur J Intern Med 2004;15:531-533.
20. Herzog-Tzarfati K, Shiloah E, Koren-Michowitz M, Minha S, Rapoport MJ: Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins. Eur J Intern Med 2006;17:439-440.
21. Scheurlen W, Ramasubbu K, Wachowski O, Hemauer A, Modrow S: Chronic autoimmune thrombopenia/neutropenia in a boy with persistent parvovirus B19 infection. J Clin Virol 2001;20:173-178.
22. Barlow GD, McKendrick MW: Parvovirus B19 causing leucopenia and neutropenia in a healthy adult. J Infect 2000;40:192-195.